Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × melflufen × Plasma cell × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 16 daratumumab 9 Bortezomib 9 Lenalidomide 6 pomalidomide 4 carfilzomib 4 isatuximab 3 selinexor 2 Thalidomide 2 Prednisone 2 Melphalan 2 trametinib 1 talquetamab 1 montelukast 1 melflufen 1 idecabtagene vicleucel 1 darlin protein, Dictyostelium 1 dabrafenib 1 belantamab mafodotin 1 L-melphalanyl-p-L-fluorophenylalanine ethyl ester 1 Diphenhydramine 1 Acetaminophen 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02963493 2022-11-22

HORIZON

Oncopeptides AB

Phase 2 Completed

157 enrolled 26 charts 1 FDA

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡